SCHEMBL19785096

SCHEMBL19785096

CNc1nccc(SCCC(=O)OC)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.43
POLB P06746 2/20 0.43
PRNP P04156 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
GSTP1 P09211 1/20 0.40
GSTM2 P28161 1/20 0.40
CXCR1 P25024 1/20 0.37
CXCR2 P25025 1/20 0.37
ALDH1A1 P00352 3/20 0.36
MEN1 O00255 1/20 0.36
RAB9A P51151 1/20 0.36
MAPT P10636 4/20 0.36
ABL1 P00519 1/20 0.36
RIN1 Q13671 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
LMNA P02545 2/20 0.34
HSD17B10 Q99714 2/20 0.33
PTGS1 P23219 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21856186 0.85 TNF (0.40) KMT2APOLBPRNPRXFP1GSTP1
SCHEMBL29506060 0.85 KMT2A (0.45) KMT2APOLBPRNPRXFP1GSTP1
SCHEMBL18319841 0.85 KMT2A (0.45) KMT2APOLBPRNPRXFP1GSTP1
SCHEMBL22303096 0.84 CXCR1 (0.41) KMT2APOLBPRNPRXFP1GSTP1
SCHEMBL21855767 0.84 KMT2A (0.39) KMT2APOLBPRNPRXFP1GSTP1
SCHEMBL18320486 0.84 KMT2A (0.44) KMT2APOLBPRNPRXFP1GSTP1
SCHEMBL29603922 0.84 KMT2A (0.44) KMT2APOLBPRNPRXFP1GSTP1
SCHEMBL19785098 0.83 KMT2A (0.43) KMT2APOLBPRNPRXFP1GSTP1
SCHEMBL30660933 0.83 KMT2A (0.43) KMT2APOLBPRNPRXFP1GSTP1
SCHEMBL18320494 0.83 KMT2A (0.43) KMT2APOLBPRNPRXFP1GSTP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441743-B2 Spiro aromatic ring compound and use thereof ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) 2025-10-14 US disclosed
WO-2024175081-A1 SHP2 INHIBITOR COMPOUND AND USE THEREOF 深圳真实生物医药科技有限公司 2024-08-29 WO disclosed
CN-111566104-B Spiro aromatic ring compound and application thereof 上海奕拓医药科技有限责任公司 2024-05-17 CN disclosed
US-20240124453-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2024-04-18 US disclosed
US-20240116949-A1 SPIRO AROMATIC RING COMPOUND AND USE THEREOF ETERN BIOPHARMA SHANGHAI CO LTD (CN) 2024-04-11 US disclosed
US-11884664-B2 Protein tyrosine phosphatase inhibitors ARRAY BIOPHARMA INC. (US) 2024-01-30 US disclosed
EP-3484856-B1 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS REVOLUTION MEDICINES INC (US) 2023-11-15 EP disclosed
US-11685748-B2 Spiro aromatic ring compound and application thereof ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) 2023-06-27 US disclosed
US-11685748-B2 Spiro aromatic ring compound and application thereof ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) 2023-06-27 US disclosed
US-11685748-B2 Spiro aromatic ring compound and application thereof ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) 2023-06-27 US disclosed
US-10844079-B2 Spiro aromatic ring compound and application thereof ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) 2020-11-24 US disclosed
US-20200317695-A1 SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) 2020-10-08 US disclosed
US-20200317695-A1 SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) 2020-10-08 US disclosed
US-20200317665-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2020-10-08 US disclosed
WO-2020201991-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2020-10-08 WO disclosed
EP-3712151-A1 SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF Etern Biopharma (Shanghai) Co., Ltd. (CN) 2020-09-23 EP disclosed
EP-3712151-A1 SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF Etern Biopharma (Shanghai) Co., Ltd. (CN) 2020-09-23 EP disclosed
CN-111592525-A Spiro aromatic ring compound and application thereof 上海奕拓医药科技有限责任公司 2020-08-28 CN disclosed
CN-111566104-A Spiro aromatic ring compound and application thereof 上海奕拓医药科技有限责任公司 2020-08-21 CN disclosed
WO-2018013597-A1 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS Revolution Medicines, Inc. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11884664-B2 Protein tyrosine phosphatase inhibitors PPM1A, PPM1F, PPP5C KMT2A 2258/4885POLB 2681/4885PRNP 1522/4885
US-20200317665-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS PPM1A, PPM1F, PPP5C KMT2A 2258/4885POLB 2681/4885PRNP 1522/4885
US-20240124453-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS PPM1A, PPM1F, PPP5C KMT2A 2258/4885POLB 2681/4885PRNP 1522/4885
US-20240116949-A1 SPIRO AROMATIC RING COMPOUND AND USE THEREOF PTPN1, PTPN11, PTPN5 KMT2A 2455/4885POLB 4662/4885PRNP 2999/4885
US-12441743-B2 Spiro aromatic ring compound and use thereof PTPN1, PTPN11, PTPN5 KMT2A 2455/4885POLB 4662/4885PRNP 2999/4885
US-10844079-B2 Spiro aromatic ring compound and application thereof PTPN1, PTPN11, PTPN5 KMT2A 2397/4885POLB 4665/4885PRNP 3020/4885
US-20200317695-A1 SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF PTPN1, PTPN11, PTPN5 KMT2A 2397/4885POLB 4665/4885PRNP 3020/4885
US-11685748-B2 Spiro aromatic ring compound and application thereof PTPN1, PTPN11, PTPN5 KMT2A 2397/4885POLB 4665/4885PRNP 3020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.